On July 11, 2025, BTIG updated its rating for Apogee Therapeutics (NASDAQ:APGE) to a "Buy" recommendation. At the time, the stock was priced at $38.14. BTIG also raised the price target for Apogee from $100 to $115. Apogee Therapeutics is a biopharmaceutical company focused on developing therapies for immune-mediated diseases. It competes with other companies in the biotech sector, such as Regeneron Pharmaceuticals and Sanofi, which produce the well-known drug Dupixent.
Apogee Therapeutics recently announced positive results from its Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody for treating moderate-to-severe atopic dermatitis. The trial's Part A met all primary and key secondary endpoints, achieving a 71% decrease from baseline in the Eczema Area and Severity Index (EASI) at Week 16. This success likely contributed to BTIG's optimistic outlook and increased price target. The trial also demonstrated an EASI-75 of 66.9%, with a 42.5% placebo-adjusted efficacy, marking the highest topline and placebo-adjusted efficacy of any biologic in a global study. This strong performance positions APG777 as a potentially best-in-class treatment, which could drive future growth for Apogee. The ongoing APEX Part B trial is testing higher exposures, with results expected by mid-2026, paving the way for Phase 3 initiation.
APG777 was well tolerated, showing a favorable safety profile consistent with other agents in its class. This is crucial for regulatory approval and market acceptance. Additionally, Apogee has begun dosing the first patient in the APG279 (IL-13 + OX40L) Phase 1b head-to-head trial versus Dupixent, with results expected in the second half of 2026. This trial could further strengthen Apogee's competitive position in the market. Currently, APGE is priced at $38.14, reflecting a decrease of 1.11% or $0.43. The stock has fluctuated between $37.49 and $38.78 during the day. Over the past year, it reached a high of $63.50 and a low of $26.20. With a market capitalization of approximately $2.27 billion and a trading volume of 730,239 shares, Apogee remains a significant player in the biotech industry.
